{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.09","upperLimit":"30.13","value":"9.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"EBV positive related gastric cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.90","upperLimit":"36.50","value":"20.44"},{"groupId":"OG001","lowerLimit":"9.49","upperLimit":"26.78","value":"17.08"},{"groupId":"OG003","lowerLimit":"2.50","upperLimit":"35.06","value":"8.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"HPV positive SCCHN"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"6.83","upperLimit":"29.54","value":"12.12"},{"groupId":"OG002","lowerLimit":"4.37","upperLimit":"30.59","value":"14.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Other anogenital HPV associated cancers"},{"categories":[{"measurements":[{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG004","lowerLimit":"1.68","upperLimit":"NA","value":"4.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"SCCHN I-O naive"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.25","upperLimit":"44.85","value":"21.55"},{"groupId":"OG001","lowerLimit":"10.22","upperLimit":"34.79","value":"17.12"},{"groupId":"OG002","lowerLimit":"14.62","upperLimit":"32.82","value":"22.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Randomized"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"14.39","upperLimit":"29.04","value":"20.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Pooled"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.88","upperLimit":"23.72","value":"10.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Vaginal/Vulvar"},{"categories":[{"measurements":[{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG000","lowerLimit":"23.26","upperLimit":"NA","value":"80.66"},{"groupId":"OG001","lowerLimit":"8.51","upperLimit":"48.33","value":"29.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"MCC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.62","upperLimit":"35.29","value":"22.74"},{"groupId":"OG001","lowerLimit":"16.82","upperLimit":"41.43","value":"23.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"NPC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"195"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from first dosing date to the date of death. A participant who has not died will be censored at last known date alive. Participants with the following diseases will be assessed:\n\n1. EBV positive related gastric cancer;\n2. HPV positive SCCHN;\n3. Other anogenital HPV associated cancers;\n4. GYN (Cervical, Vaginal, Vulvar) carcinoma;\n5. Merkel cell carcinoma (MCC);\n6. Nasopharyngeal carcinoma (NPC) Note: \"Cervical, Randomized\" and \"Cervical, Pooled\" are not mutually exclusive categories","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab IV over 30 minutes at 240 mg every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG000","title":"Metastatic Monotherapy"},{"description":"Nivolumab 3 mg/kg IV over 30 minutes every 2 weeks + Ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG001","title":"Metastatic Combo A"},{"description":"Nivolumab 1 mg/kg IV over 30 minutes + Ipilimumab 3 mg/kg IV over 30 minutes every 3 weeks for 4 doses followed by Nivolumab 240 mg IV over 30 minutes every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG002","title":"Metastatic Combo B"},{"description":"Nivolumab 240 mg IV over 30 minutes + BMS-986016 (Relatlimab) 80 mg IV over 60 minutes administered every 2 weeks for a maximum of 24 months, or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG003","title":"Metastatic Combo C"},{"description":"Daratumumab 16 mg/kg IV weekly for the first 8 weeks. Starting at Week 3, Nivolumab 240 mg IV over 30 minutes every 2 weeks. Daratumumab 16 mg/kg every 2 weeks from Weeks 9-24. Starting at Week 25, Nivolumab 480 mg IV flat dose over 30 minutes every 4 weeks; daratumumab 16 mg/kg every 4 weeks for a maximum of 24 months or until progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG004","title":"Metastatic Combo D"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the metastatic cohorts","reportingStatus":"POSTED","timeFrame":"From the first dosing date to the date of death (Up to 83 months)","title":"Metastatic: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}